ARCHIVES

Gleevec Improves Survival Of CML In Accelerated Phase

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

Other Contract Concepts Approved By DCE Board

March 10, 1989

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014

Attacks On Cancer, Program Peak Following Post Series; Defenders Cite Inaccuracies, Misconceptions

November 6, 1981

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

ADT May Increase Risk Of Cardio Events In Prostate Cancer Patients

February 5, 2010

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

March 21, 2008